Epsilon M&A Deal Report - Zellbios
Transaction Multiples for the Valuation of Private Companies
Private Group led by DPE Deutsche Private Equity / Zellbios
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
---|---|---|---|---|---|---|---|---|
Historic | ![]() |
![]() |
||||||
Current |
![]() |
Multiple available |
n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
Date | Acquirer | Target | Country | Multiples | See details |
13/03/2014 | Charles River Laboratories International | CRO services division of Galapagos NV (Argenta and BioFocus) | Netherlands | ** | 63103 |
06/01/2014 | Henry Schein | Five Arseus companies in Belgium, France and the Netherlands | Belgium | * | 63097 |
Source: Epsilon Research / EMAT